Latest Fenofibrate Stories
PRINCETON, N.J., Nov. 5, 2014 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL) announced today that the Company has received approval from the U.S.
LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019” to its store.
The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 percent in women with type-2 diabetes, a new University of Sydney study reveals.
New guidelines for the treatment of high cholesterol are not appropriate for people with type 2 diabetes – or are they?
MONTGOMERY, Ala., June 3, 2014 /PRNewswire/ -- H2-Pharma, LLC announced today the launch of Fenofibrate 50 mg and 150 mg capsules, an authorized generic version of LIPOFEN®.
Data suggest lower risk of major adverse cardiovascular events and death, especially in patients with diabetes or prior coronary heart disease ORLANDO, Fla., May 2, 2014 /PRNewswire/ --
A drug called atrasentan provides health benefits for patients who have both diabetes and kidney disease.
Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY)
An educational toolkit designed to improve care of patients with diabetes was not effective, Baiju R Shah and colleagues (University of Toronto) found in a cluster randomized trial conducted in 2009-2011.
Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus.